Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy

Joseph Martin Alisky


Treatment of stave IV renal cell cancer and melanoma with intravenous interleukin-2 (IL-2) is often limited by side effects, and only a minority of patients obtain sustained remissions. This editorial proposes that infusing IL-2 into the splenic artery will allow much stronger immune activation without systemic side effects, achieving a superior clinical response and enabling treatment of patients currently excluded from IL-2 by medical comorbidities.


Cite this article as: Alisky JM. Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy. Int J Cancer Ther Oncol 2014; 2(1):020115.

DOI: http://dx.doi.org/10.14319/ijcto.0201.15



Interleukin-2; Cytokines; Treatment Protocols

Full Text:



Kondadasula SV, Varker KA, Lesinski GB, et al. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. Cancer Immunol Immunother 2008; 57:1137-49.

Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-32.

Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001; 24:287-93.

Naito K, Pellis NR, Kahan BD. Continuous intrasplenic interleukin-2 combined with antigen-specific chemoimmunotherapy. Arch Surg 1986; 121:1415-20.

Klasa RJ, Silver HK, Kong S. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res 1990; 50:4906-10.

Lygidakis NJ, Berberabe AE, Spentzouris N, et al. Targeting locoregional immunochemotherapy with new drugs in metastatic liver disease: a promising alternative. Hepatogastroenterology 1998; 45: 2248-51.

Lygidakis NJ, Safioleas M, Sgourakis G, et al. Metastatic melanoma: transplenic immunostimulation-- a new therapeutical alternative for an ever-challenging disease. Hepatogastroenterology 1999; 46:148-56.

Lygidakis NJ. Unresectable metastatic liver disease: new therapeutical alternatives. Hepatogastroenterology 1999; 46 Suppl: 1297-305.

Boura P, Kountouras J, Lygidakis NJ, et al. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters. Hepatogastroenterology 1999; 46: 799-803.

Keilholz U, Scheibenbogen C, Brado M, et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 1994; 30A:103-5.

Okuno K, Ohnishi H, Koh K, et al. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer. Biotherapy 1992; 4:257-65.

Okuno K, Ohnishi H, Nakajima I, et al. Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. Surg Today 1994; 24:80-4.

Abdel-Wahab M, El-Shennawy F, Agha S, et al. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Hepatogastroenterology 1999; 46 Suppl 1:1293-6.

Camba L, Aldrighetti L, Ciceri F, et al. Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. Br J Haematol 2001; 114:638-40.

Carrington BM, Thomas NB, Johnson RJ. Selective splenic arteriography for interleukin-2 administration: radiologic complications from the initial 113 procedures. Eur J Radiol 1992; 14:13-7.

Misfeldt ML, Grimm DR. Sinclair miniature swine: an animal model of human melanoma. Vet Immunol Immunopathol 1994; 43:167-75.

Oxenhandler RW, Adelstein EH, Haigh JP, et al. Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol 1979; 96:707-20.

Cui J, Chen D, Misfeldt ML, et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8:60-3.

Pathak S, Multani AS, McConkey DJ, et al. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol 2000; 17:1219-24.

DOI: http://dx.doi.org/10.14319/ijcto.0201.15

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.


International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)

© International Journal of Cancer Therapy and Oncology (IJCTO)

To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.


Number of visits since October, 2013